Skip to main content
Pharmadrug Inc. logo

Pharmadrug Inc. — Investor Relations & Filings

Ticker · PHRX ISIN · CA71716W2040 LEI · 529900PHQPAWL5ITEB39 CSE Manufacturing
Open in API
Filings indexed 475 across all filing types
Latest filing 2021-08-27 Regulatory Filings
Country CA Canada
Listing CSE PHRX

About Pharmadrug Inc.

https://pharmadrug.ca/

Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines. The company's primary focus areas include the clinical development of reformulated natural-based medicines aimed at treating unmet needs in oncology and infectious diseases. Additionally, Pharmadrug develops synthetic and biosynthetic formulations of existing drugs, specifically addressing opportunities related to the potential third wave of drug policy reform concerning controlled substances.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2021. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (2941 characters), consistent with a certification letter rather than a full report.
2021-08-27 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2021. The text is primarily a certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. The document length is short (2953 characters), and it fits the criteria of an officer certification rather than the interim report itself. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS), not as the interim report (IR).
2021-08-27 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis For the Three and Six Months Ended June 30, 2021' and contains detailed management commentary on financial condition, business overview, corporate developments, financing activities, and outlook. It references compliance with National Instrument 51-102, discusses interim financial statements, and includes substantive financial and operational analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document is approximately 15,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is IR with high confidence. H1 2021
2021-08-27 English
News release - English.pdf
Regulatory Filings
2021-08-25 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the appointment of a new auditor for PharmaDrug Inc. It references the filing of a Notice of Change of Auditor and related letters on SEDAR, which are regulatory filings. The document does not contain any financial statements, audit reports, or detailed audit information itself, but rather announces a change in auditor and points to other filings. The document length is short (2418 characters), and it is clearly an announcement rather than a full audit report or annual report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about auditor change.
2021-08-06 English
Letter from successor auditor.pdf
Regulatory Filings Classification · 95% confidence The document is a letter addressed to multiple Canadian securities commissions regarding a change of auditor notice. It references a specific regulatory requirement (National Instrument 51-102) and states that the auditor has reviewed the notice but does not agree or disagree with its content. The document is short (806 characters) and does not contain any financial statements or substantive financial data. It is essentially an auditor's attestation or certification related to a regulatory filing. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as an audit report or annual report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-08-06 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.